Frazier Life Sciences Management, L.P. Vaxcyte, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.9 Billion
- Q2 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 474,405 shares of PCVX stock, worth $20.2 Million. This represents 0.81% of its overall portfolio holdings.
Number of Shares
474,405
Previous 539,405
12.05%
Holding current value
$20.2 Million
Previous $20.4 Million
24.28%
% of portfolio
0.81%
Previous 1.28%
Shares
10 transactions
Others Institutions Holding PCVX
# of Institutions
324Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$627 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$512 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$510 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$424 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$256 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.53B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...